Tesamorelin Dosage Chart and Schedule
FDA-approved
GHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.
Also called: Egrifta, Egrifta SV, Egrifta WR
Regulatory status (US)
FDA-approved since 2010 (Egrifta) to reduce excess abdominal fat in adults with HIV and lipodystrophy. Egrifta WR replaced Egrifta SV in 2025. It has no approved use for general fat loss or anti-aging.
What it is
A synthetic version of growth-hormone-releasing hormone (GHRH) that makes the pituitary release growth hormone, which raises IGF-1.
Label doses
| Product | Daily dose | How it is mixed |
|---|---|---|
| Egrifta WR (11.6 mg vial) | 1.28 mg under the skin once daily | 1.3 mL bacteriostatic water per the label; one vial lasts 7 days |
| Egrifta SV (2 mg vial) | 1.4 mg once daily | Older product, replaced by WR |
From the Egrifta labels. The products are not interchangeable mg for mg; follow the instructions for the exact product.
Tesamorelin reconstitution calculator
Enter your vial and your prescribed dose to see the units on a U-100 syringe.
What human studies show
- Approved on the basis of trials in adults with HIV and lipodystrophy; dosing below is from the labels.
Storage
- Egrifta WR: store at room temperature; discard the mixed solution 7 days after reconstitution.
Safety
- Contraindicated in pregnancy, with disruption of the hypothalamic-pituitary axis and with active cancer.
- Label instructions for mixing and measuring take priority over any generic calculator.
Questions
- Is Tesamorelin FDA-approved?
- FDA-approved since 2010 (Egrifta) to reduce excess abdominal fat in adults with HIV and lipodystrophy. Egrifta WR replaced Egrifta SV in 2025. It has no approved use for general fat loss or anti-aging.
- What dose of Tesamorelin has been studied?
- Egrifta WR (11.6 mg vial): 1.28 mg under the skin once daily: 1.3 mL bacteriostatic water per the label; one vial lasts 7 days; Egrifta SV (2 mg vial): 1.4 mg once daily: Older product, replaced by WR. From the Egrifta labels. The products are not interchangeable mg for mg; follow the instructions for the exact product.
- How many units is my Tesamorelin dose?
- Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.
Related
Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.
SemaglutideWeekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).
Orforglipron (Foundayo)Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.
Elamipretide (SS-31)Mitochondria-targeted peptide (Forzinity), approved 2025 only for Barth syndrome. Label: 40 mg daily.
Sources
- DailyMed: Egrifta (tesamorelin) labeling
- FDA label: Egrifta WR (tesamorelin) 2025
- FDA 510(k) K212499: BD insulin syringes for U-100 insulin
Last checked 2026-11-16. How we pick and check sources: methodology.